Frelii, Inc. (OTC: FRLI), interview with CEO Ian Jenkins discussing the company's personalized medicine technology which uses human DNA gene sequencing and artificial intelligence (AI) to assess more than 3.2 billion markers on the human genome.
Ian explains how Frelii is starting to commercialize it's technology with initial applications in medical cannabis, and psychotropic medicines.
. . .
This content is available to members only.
If you are an existing member, please LOGIN
Note a member? Sign up and get immediate access. $195 quarterly (90 days of full access).
Register New Account
Are you interested in PROFITS like these?
+100% increase in 5 days.
+258% increase in 47 days.
+310% increase 34 days.
These are the type of profits Wall Street Reporter subscribers, had the opportunity to bank in just past few months. And of course, there have been dozens of 10X gainers (and more), over the past 20 years we have been online.
It’s no wonder that WallStreetReporter.com is the best kept secret amongst top-performing hedge-funds, family offices, and sophisticated investors worldwide.
What’s our secret?
We focus on companies at key inflection points, and undergoing positive material change, which can drive stock prices higher within 3-6 months.
Once Wall Street Reporter identifies these companies, we the interview the CEO in a recorded audio interview for our subscribers.
These exclusive, in-depth 25-40 min interviews, give you the opportunity to listen-in, as CEO’s candidly share their company’s “investment story” in their own words. Unscripted, unfiltered, with no edits.
We ask these CEO’s questions which help investors better understand a company’s fundamentals, but even more important - gain a sense of management’s values, credibility, confidence and ability to execute.
But most importantly - it’s not what these CEO’s say - it’s HOW they say it. Subtle verbal cues, subtext, and tonality in these audio interviews - give valuable clues and allow the sophisticated investor to gain valuable insights you can’t get anywhere else.
In fact, many institutional investors say they gain far greater insights from Wall Street Reporter’s CEO interviews, than even in face-to-face meetings with management.
This management access, gives investors a profitable edge, enabling them to understand a company’s upside potential, in the proper context, straight from the source.
As a subscriber, you will gain insights into the quality of management, and corporate strategy, you can not get anywhere else.
Wall Street Reporter’s exclusive CEO interviews give you a true insider perspective. If you are looking for a true, “qualitative research advantage”, this is it.
It’s no wonder that so many top-performing hedge fund managers, and analysts use Wall Street Reporter’s interviews as a key step in their research process.
Investment Bankers and Direct Investors can gain insight into deal flow opportunities. From M&A to PIPES, and Direct Lending - you will gain an informational edge by knowing how the CEO’s think and what their companies needs are for potential financing or strategic growth opportunities.
Subscribe now for only $195/Quarterly. That’s a full 90 days of access.
All you need is to pick up one good idea, and it will more than pay for your subscription 100-fold.
Register New Account
Institutional / team access subscriptions, contact Melissa Walters 212-871-2057 ext 2